Grünenthal announced today that its U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and ...

"Patients who undergo surgery and end up developing post-surgical neuropathic pain, may experience debilitating complications that often are not treated appropriately," says Lizandra Marcondes, M.D., ...

The FDA has placed a trial of Rapport Therapeutics’ epilepsy drug for a type of nerve pain on hold while the biotech tweaks ...

“Patients who undergo surgery and end up developing post-surgical neuropathic pain, may experience debilitating complications that often are not treated appropriately,” says Lizandra Marcondes, M.D., ...

Key Highlights Dogwood Therapeutics Proprietary Pipeline Includes: Halneuron ® is in Phase 2b development as a non-opioid, NaV 1.7 inhibitor to treat the neuropathic pain associated with chemotherapy ...

Research and development expense was $15.5 million for the third quarter of 2024, as compared to $7.6 million for the prior ...

Many types of medications, including over-the-counter (OTC) and prescription drugs, can help relieve joint pain due to ...

Neuropathic pain affects more than 20 million people in the U.S., and at least a quarter of these cases are puzzling for ...

ITDD helps effectively manage chronic pain and spasticity in some patients but requires adherence to best practices and a ...

A recent study has raised concerns about the widespread prescription of antidepressants for chronic pain, warning that many ...

OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an ...

The Company’s novel pipeline is based on Nobel Prize winning research and includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for ...